We­govy, Ozem­pic ex­clu­siv­i­ty chal­lenges de­nied by US patent ap­peal board

The US Patent and Trade­mark Of­fice’s Patent Tri­al and Ap­peal Board has de­clined to re­view two patent chal­lenges around No­vo Nordisk’s semaglu­tide brought by gener­ics mak­er My­lan Phar­ma­ceu­ti­cals.

My­lan, now part of Vi­a­tris, pe­ti­tioned the PTO to re­view key patents pro­tect­ing semaglu­tide, the ac­tive in­gre­di­ent in No­vo Nordisk’s GLP-1 type 2 di­a­betes block­buster Ozem­pic and weight loss drug We­govy. Vi­a­tris re­port­ed in its re­cent sec­ond quar­ter earn­ings pre­sen­ta­tion that its gener­ic ver­sions for both Ozem­pic and We­govy were un­der reg­u­la­to­ry re­view.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER